Pharmaceutical

Sensorion raises $16m for gene therapies to treat deafness

Sensorion expects results from a Phase I/II trial of its lead candidate SENS-501 in the second half of 2025.

Apr 9, 2024 - 00:00
Sensorion raises $16m for gene therapies to treat deafness
Sensorion expects results from a Phase I/II trial of its lead candidate SENS-501 in the second half of 2025.
Read the original article

Tags:

Previous Article

Pharmaceutical solid dose (commercial dose) manufacturing companies in contract ...

Next Article

AdAlta and SYNthesis to form AdCella for advanced cancer treatments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The emergency room is where the United States’ social problems come home to roost

Opinion: The emergency room is where the United States’...

Jan 30, 2024

Opinion: The best way to convince healthy people to get insurance is not ‘because it’s in your financial interest’

Opinion: The best way to convince healthy people to get...

Nov 3, 2023

FDA extends review of GSK’s myelofibrosis drug

FDA extends review of GSK’s myelofibrosis drug

Jun 19, 2023